(Q59396622)
Statements
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study (English)
Victoria Birlutiu
Pavol Jarcuska
Sorin Claudiu Man
Radu Vladareanu
Dorothée Meric
Kurt Dobbelaere
Florence Thomas
Dominique Descamps